logo-loader
viewInstem PLC

Instem welcomes significant contract extension for SEND platform

Phil Reason, chief executive at Instem Plc (LON:INS), discusses with Proactive's Polly Middlehurst a significant contract extension from a company using their SEND platform.

The client, described as a top-five pre-clinical contract research organisation, has increased the size of the deal by US$400,000 to US$500,000.

Quick facts: Instem PLC

Price: 490 GBX

AIM:INS
Market: AIM
Market Cap: £81.7 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Instem PLC named herein, including the promotion by the Company of Instem PLC in any Content on the Site, the Company receives from said issuer...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Instem PLC's Phil Reason says they've been really busy during lockdown and...

Instem PLC's (LON:INS) Phil Reason speaks to Proactive London's Andrew Scott after announcing they've won a contract worth US$1mln to provide services to Biotoxtech, which runs the largest non-clinical research and development facility in South Korea. Reason adds that they've been 'really busy'...

2 days, 4 hours ago

2 min read